Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology

Further Publications Immunology

Recurrence Risk in Pediatric Non-Infectious Uveitis during Adalimumab Tapering: An International Multicenter Retrospective Study

Arthritis Rheumatol

Marino A, Cicinelli MV, Miserocchi E, Costi S, Baldo F, Gattinara MV, Scandale P, Smith SD, Goldstein DA, Baddar D, Gerges TK, Janetos TM, Ruiz-Cruz M, Maruyama K, Serafino M, Camicione P, Gupta V, Amer R, Dodds EM, Inchauspe S, Munk MR, Carreño E, Chee SP, Agarwal A, Schlaen A, Gómez RA, Couto CA, Khairallah M, Neri P, Chighizola CB, Caporali RF, Pichi F

doi: 10.1002/art.43165

Immunodeficiency

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

J Clin Immunol

Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, Wedner HJ, Scarupa M, Mondou E, Nanaware-Kharade N, Hanna K, Coll MQ, Oliveras J

doi: 10.1007/s10875-025-01952-5

Rheumatoid Arthritis

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm

Ann Rheum Dis

Hetland ML, Heiberg MS, Sokka-Isler T, Rudin A, Østergaard M, Haavardsholm E, Rutanen J, van Vollenhoven R, Grondal G, Ørnbjerg LM, Bøyesen P, Lampa J, Nurmohamed M, Gudbjornsson B, Uhlig T, Kononoff A, Lend K, Krabbe S, Olsen IC, Sexton J, Hørslev-Petersen K

doi: 10.1016/j.ard.2025.03.002

Further Publications Rheumatology

Clinical and laboratory predictors of diagnostic delay in childhood Takayasu arteritis and polyarteritis nodosa: a retrospective cohort study

Rheumatology (Oxford)

Ercan Emreol H, Başaran O, Bayındır Y, Cam V, Ünal D, Erkan MO, Banak ÖN, Dara Kar HD, Sag E, Bilginer Y, Ozen S

doi: 10.1093/rheumatology/keaf661

Systemic Lupus Erythematosus

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial

Arthritis Care Res (Hoboken)

Brunner HI, Antón J, Calvo-Penadés I, Dimelow R, Horneff G, Kamphuis S, Marino R, van Maurik A, Minden K, Mori M, Ocran-Appiah J, Wilkinson C, Yamasaki Y, Assudani D, Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators

doi: 10.1002/acr.25700

Psoriasis

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Adv Ther

Deodhar S, Loganathan S, Kadadanamari Subbarama Reddy R, Ranganna GM, Liu S, Hummel MA, Daniluk S, Hanczewska A, Vekovska K, Zegadlo-Mylik M, Pulka G, -Holz EW

doi: 10.1007/s12325-025-03240-5

Systemic Lupus Erythematosus

Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics

Rheumatology (Oxford)

Singh JA, Hearld LR, Eisen S, Chatham WW, Narain S, Annapureddy N, Kamen DL, Trotter K, Majithia V, Lee Ching C, Aouhab Z, Venuturupalli S, Wallace DJ, Ramsey-Goldman R, Kim A, McMahon M, Sam Lim S, Bhairavarasu K, Meara A, Kalunian K, Beasley M, Implementing DEcision-Aid for Lupus in clinics (IDEAL) Consortium

doi: 10.1093/rheumatology/keaf205

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Juvenile Idiopathic Arthritis

Allogeneic hematopoietic stem cell transplantation for severe Still's disease: a retrospective report of 3 pediatric patients

Rheumatology (Oxford)

Schmutz M, Cognard J, Hadchouel A, Berteloot L, Hentgen V, Pietrement C, Eveillard LA, Bastard P, Castelle M, Chbihi M, Levy R, Welfringer-Morin A, Pouletty M, Quartier P, Neven B, Moshous D, Fournier B, Frémond ML

doi: 10.1093/rheumatology/keaf416

Related content

Recurrence Risk in Pediatric Non-Infectious Uveitis during Adalimumab Tapering: An International Multicenter Retrospective Study

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

Clinical and laboratory predictors of diagnostic delay in childhood Takayasu arteritis and polyarteritis nodosa: a retrospective cohort study

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Allogeneic hematopoietic stem cell transplantation for severe Still's disease: a retrospective report of 3 pediatric patients